Association between serum @entity4613 and @entity460 , long-term blood pressure, and mortality in treated XXXX adults.

@entity1 @entity101 @entity353 @entity4613 @entity740 @entity79 @entity460 @entity65
OBJECTIVES: @entity79 are associated with @entity65 and mortality in @entity1 with @entity740 and the general population. METHODS: We assessed the impact of baseline serum @entity4613 and @entity460 on longitudinal blood pressure (BP) control and survival in @entity101 adults. We studied 9260 @entity101 adults followed for 40 years (151789 @entity1 -years). Changes in BP over initial 5-year follow-up were analysed using generalized estimating equations. Survival analyses were performed using Cox proportional hazards model. RESULTS: Serum @entity4613 levels were higher in @entity101 @entity1 (1.10mmol/l  0.20) than compared to @entity1 (1.02mmol/l  0.21). In treated @entity101 @entity1 , higher baseline serum @entity4613 was significantly associated with poor @entity353 (one standard deviation increase in @entity4613 was associated with 0.22 and 0.59 mmHg higher SBP at 5 years in @entity1 and @entity1 , respectively). Higher serum @entity4613 was significantly associated with all-cause and @entity65 in @entity1 , whereas in @entity1 and women, serum @entity460 significantly predicted all-cause and noncardiovascular mortality. In @entity101 @entity1 with @entity740 , higher @entity4613 was significantly associated with poorer survival. CONCLUSION: In @entity101 patients, serum @entity4613 and @entity460 are significantly associated with reduced all-cause and cardiovascular survival and this appears not to be related to BP control.
